Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;10(2):243-251.
doi: 10.1177/1756283X16681701. Epub 2017 Jan 5.

The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease

Ronnie Fass  1 , Rosita Frazier  2
Affiliations
Review

The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease

Ronnie Fass et al. Therap Adv Gastroenterol. 2017 Feb.

Abstract

Dexlansoprazole modified-release (MR) is the R-enantiomer of lansoprazole and is currently the only proton-pump inhibitor (PPI) with a novel dual delayed release (DDR) formulation. Overall, dexlansoprazole MR demonstrates a similar safety and side-effect profile as lansoprazole. Dexlansoprazole MR has been shown to be highly efficacious in healing erosive esophagitis, maintaining healed esophageal mucosa in patients with erosive esophagitis and controlling symptoms of patients with nonerosive reflux disease (NERD). Recent studies have also demonstrated that dexlansoprazole MR is highly effective in improving nocturnal heartburn, gastroesophageal reflux disease (GERD) related sleep disturbances and bothersome regurgitation. Dexlansoprazole MR is well tolerated and can be taken without regard to food.

Keywords: dexlansoprazole modified-release; gastroesophageal reflux disease; proton-pump inhibitor.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Ronnie Fass is a speaker for Takeda Pharmaceuticals.

References

    1. Locke GR, III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448–1456. - PubMed
    1. El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastroesophageal reflux disease: a systematic review. Gut 2014; 63: 871–880. - PMC - PubMed
    1. Nebel OT, Fornes MF, Castell DO. Symptomatic gastro-esophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953–956. - PubMed
    1. Fass R, Ofman JJ. Gastroesophageal reflux disease – should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97:1901–1909. - PubMed
    1. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. TCP in Gasroenteral 2007; 41: 131–137. - PubMed

LinkOut - more resources